MEDULLARY THYROID CANCER AS PART OF MEN 2B SYNDROME. CASE REPORT
https://doi.org/10.17650/2222-1468-2013-0-4-23-28
Abstract
MEN 2B syndrome is a subtype of the multiple endocrine neoplasia type 2. It is characterized by the development of aggressive forms of medullary thyroid cancer at an early age, pheochromocytoma and hyperparathyroid syndrome. This article provides an own clinical observation of the patient with MEN 2B syndrome associated with a mutation in the proto-oncogene RET.
About the Authors
L. N. Lyubchenko
N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
F. A. Amosenko
N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
M. G. Filippova
N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. Z. Dobrokhotova
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
E. G. Matyakin
N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Allgayer H., Render H., Fulda S. Hereditary Tumors: From genes to clinical consequences. Wiley-VCH, 2009. 530 p.
2. Zbuk K.M., Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007 Jan;7(1):35–45.
3. American Thyroid Association Guidelines Task Force, Kloos R.T., Eng C. et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009 Jun;19(6):565–612.
4. Cohen M.S., Moley J.F. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003 Jun;253(6):616–26.
5. Inabnet W.B., Caragliano P., Pertsemlidis D. Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 2000 Dec;128(6):1007–11; discussion 1011–2.
6. Rodriguez J.M., Balsalobre M., Ponce J.L. et al. Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg 2008 Nov;32(11):2520–6.
7. Neumann H.P., Bausch B., McWhinney S.R. et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002 May 9;346(19):1459–66.
8. Schuffenecker I., Virally-Monod M., Brohet R. et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab 1998 Feb;83(2):487–91.
9. Machens A., Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. Mol Cell Endocrinol 2006 Mar 9;247(1–2):34–40.
10. Machens A., Gimm O., Hinze R. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001 Mar;86(3):1104–9.
11. Skinner M.A., DeBenedetti M.K., Moley J.F. et al. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg 1996 Jan;31(1):177–81; discussion 181–2.
12. Moline J., Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med 2011 Sep;13(9):755–64.
13. Wray C.J., Rich T.A., Waguespack S.G. et al. Failure to recognize multiple endocrine neoplasia 2B: more common than we think? Ann Surg Oncol 2008 Jan;15(1):293–301.
14. Mulligan L.M., Kwok J.B., Healey C.S. et al. Germ-line mutations of the RET protooncogene in multiple endocrine neoplasia type 2A. Nature 1993 Jun 3;363(6428):458–60.
15. Donis-Keller H., Dou S., Chi D. et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993 Jul;2(7):851–6.
16. Takahashi M., Ritz J., Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985 Sep;42(2):581–8.
17. ARUP Online Scientific Resourse. www.arup.utah.edu.
18. Eng C., Clayton D., Schuffenecker I. et al.The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996 Nov 20;276(19):1575–9.
19. Machens A., Gimm O., Hinze R. et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001 Mar;86(3):1104–9 .
20. Yip L., Cote G.J., Shapiro S.E. et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003 Apr;138(4):409–16; discussion 416.
21. Gimm O., Ukkat J., Niederle B.E. et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004 Dec;28(12):1312–6.
22. Machens A., Niccoli-Sire P., Hoegel J. et al. Early malignant progression of hereditary medullary thyroid carcinoma. N Engl J Med 2003 Oct 16;349(16):1517–25.
23. ATA (American Thyroid Association).www.thyroid.org.
24. Satge D., Philippe E., Ruppe M. et al. Neonatal carcinoma. Review of the literature apropos of a case. Bull Cancer 1988;75(4):373–84.
25. Castellone M.D., Verrienti A., Magendra Rao D. et al. A novel de novo germline V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol (Oxf) 2010 Oct;73(4):529–34.
26. Chang T.J., Wu S.L., Chang T.C. et al. De novo RET proto-oncogene mutation in a patient with multiple endocrine neoplasia type 2B. J Formos Med Assoc 1999 Oct;98(10):692–7.
27. Wells S.A. Jr, Chi D.D., Toshima K. et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surgery 1994;220(3):237–47.
28. Szinnai G., Meier C., Komminoth P., Zumsteg U.W. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 2003 Feb;111(2):E132–9.
29. Lee N.C., Norton J.A. Multiple endocrine neoplasia type 2B--genetic basis and clinical expression. Surg Oncol 2000 Nov;9(3):111–8.
30. Nguyen L., Niccoli-Sire P., Caron P. et al. Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. Eur J Endocrinol 2001 Jan;144(1):37–44.
31. NCCN Clinical Practical Guidelines 2011. Thyroid carcinoma (www.nccn.org).
32. Pacak K., Ilias I., Adams K.T., Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005 Jan;257(1):60–8.
Review
For citations:
Lyubchenko L.N., Amosenko F.A., Filippova M.G., Dobrokhotova V.Z., Matyakin E.G. MEDULLARY THYROID CANCER AS PART OF MEN 2B SYNDROME. CASE REPORT. Head and Neck Tumors (HNT). 2013;(4):23-28. (In Russ.) https://doi.org/10.17650/2222-1468-2013-0-4-23-28
Views:
934
Email this article 